scholarly journals Protective Effects of Angiotensin-Converting Enzyme Inhibitors in High-Risk African American Men With Coronary Heart Disease

2009 ◽  
Vol 11 (11) ◽  
pp. 621-626 ◽  
Author(s):  
Vasilios Papademetriou ◽  
Christodoulos Kaoutzanis ◽  
Michael Dumas ◽  
Andreas Pittaras ◽  
Charles Faselis ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
African American ◽  
Heart Disease ◽  
High Risk ◽  
Enzyme Inhibitors ◽  
African American Men ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Protective Effects ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

scholarly journals POTENTIAL OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN THE TREATMENT OF PATIENTS WITH ARTERIAL HYPERTENSION AND CORONARY HEART DISEASE

2013 ◽  
Vol 12 (1) ◽  
pp. 80-87
Author(s):  
A. G. Evdokimova ◽  
V. V. Evdokimov
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Angiotensin Converting Enzyme ◽  
Arterial Hypertension ◽  
Ace Inhibitors ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Protective Effects ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

For the last 30 years, angiotensin-converting enzyme (ACE) inhibitors have been playing a key role in the management of arterial hypertension (AH) and related cardiovascular disease. This review discusses the mechanisms of action and organo-protective effects of ACE inhibitors. Enalapril is the most extensively studied and widely used in the international clinical practice ACE inhibitor. The authors analyse the results of the studies on enalapril therapy in AH, coronary heart disease (CHD), chronic heart failure, metabolic syndrome, and postmenopause. It has been demonstrated that the combination antihypertensive therapy with a β-adrenoblocker nebivolol, enalapril, and hydrochlorothiazide (such as Berlipril® Plus) is safe and effective in patients with AH and CHD. 

Sign in / Sign up

Export Citation Format

Share Document